HomeCompareASGLY vs PFE

ASGLY vs PFE: Dividend Comparison 2026

ASGLY yields 2.78% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ASGLY wins by $16.72M in total portfolio value
10 years
ASGLY
ASGLY
● Live price
2.78%
Share price
$6.88
Annual div
$0.19
5Y div CAGR
83.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$16.77M
Annual income
$14,411,537.02
Full ASGLY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — ASGLY vs PFE

📍 ASGLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodASGLYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ASGLY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ASGLY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ASGLY
Annual income on $10K today (after 15% tax)
$236.04/yr
After 10yr DRIP, annual income (after tax)
$12,249,806.47/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, ASGLY beats the other by $12,227,486.56/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ASGLY + PFE for your $10,000?

ASGLY: 50%PFE: 50%
100% PFE50/50100% ASGLY
Portfolio after 10yr
$8.41M
Annual income
$7,218,897.87/yr
Blended yield
85.84%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ASGLY
No analyst data
Altman Z
1.9
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ASGLY buys
0
PFE buys
0
No recent congressional trades found for ASGLY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricASGLYPFE
Forward yield2.78%6.13%
Annual dividend / share$0.19$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR83.5%13.2%
Portfolio after 10y$16.77M$49.6K
Annual income after 10y$14,411,537.02$26,258.71
Total dividends collected$16.55M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ASGLY vs PFE ($10,000, DRIP)

YearASGLY PortfolioASGLY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,210$509.56$9,153$693.39+$2.1KASGLY
2$12,974$979.57$8,593$849.25+$4.4KASGLY
3$15,826$1,944.31$8,336$1,066.78+$7.5KASGLY
4$21,002$4,067.53$8,437$1,384.80+$12.6KASGLY
5$31,728$9,256.72$9,013$1,875.40+$22.7KASGLY
6$57,933$23,983.10$10,306$2,680.72+$47.6KASGLY
7$137,086$75,098.50$12,820$4,101.38+$124.3KASGLY
8$451,440$304,757.88$17,673$6,826.70+$433.8KASGLY
9$2,204,170$1,721,128.52$27,543$12,591.86+$2.18MASGLY
10$16,769,999$14,411,537.02$49,560$26,258.71+$16.72MASGLY

ASGLY vs PFE: Complete Analysis 2026

ASGLYStock

AGC Inc. manufactures and sells glass, electronics, chemicals, and ceramics worldwide. The company offers architectural glass products, including laminated, insulating, wired, solar control, toughened, decorative, sound insulation, float and patterned, and industrial glasses; structural glazing systems; and automotive glass, such as laminated, tempered, and privacy glasses, as well as integrated glass antennas, patterned glazing products, and module assembly windows. It also provides glass substrates used for thin-film-transistor liquid crystal displays and OLEDs; synthetic fused silica glass, synthetic quartz crystal, silicon carbide, CMP slurry, through glass Vias, high refractive index glass, DOE diffuser, glass ceramics substrate, optical planar device, IR cut filter, aspherical glass and molded lens, micro lens array, and fly eye and condenser lens products; polycarbonate and optical sheets, thin sheets, and films; and glass frits and paste, as well as glass substrate for semiconductor packaging, and other electronic materials. In addition, the company offers cover glass for smartphones and tablet devices; glass substrates for photovoltaic devices and touch panels; specialty glass; extra clear float glass; transparent conductive oxide glass for a-Si type solar module; and ultra-thin glass for electronics devices. Further, it provides chlor-alkali, polyurethanes, fluoro, and specialty chemical products; high thermal insulation ceramics wall for furnaces; and ceramic beads, sputtering targets, abrasion resistant ceramics, alumina cement, engineering fine ceramics, and ceramics molding agent for 3D printers. Additionally, the company engages in the digital signage on glass, copper clad laminate, and plastic optical fiber businesses; and gas and solvents, and life Science business. The company was formerly known as Asahi Glass Co., Ltd. and changed its name to AGC Inc. in July 2018. AGC Inc. was founded in 1907 and is headquartered in Tokyo, Japan.

Full ASGLY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ASGLY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ASGLY vs SCHDASGLY vs JEPIASGLY vs OASGLY vs KOASGLY vs MAINASGLY vs JNJASGLY vs MRKASGLY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.